| Result |
Filter:
|
|||||||||||||||||||||||
| ID | SEQUENCE | LENGTH | VIRUS | INHIBITION/ IC50 |
UNIT | TARGET | ASSAY | PMID | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AVP0546 | MWKTPTLKYFGGFNFSQI | 18 | SARS-CoV | 58 | % | Fusion | Plaque assay | |||||||||||||||||
| AVP0547 | ATAGWTFGAGAALQIPFAMQMAY | 23 | SARS-CoV | 39 | % | Fusion | Plaque assay | |||||||||||||||||
| AVP0548 | GYHLMSFPQAAPHGVVFLHVTW | 22 | SARS-CoV | 2 | μM | Fusion | Plaque assay | |||||||||||||||||
| AVP0549 | GVFVFNGTSWFITQRNFFS | 19 | SARS-CoV | 2 | μM | Fusion | Plaque assay | |||||||||||||||||
| AVP0550 | NEVAKNLNESLIDLQELGKYEQYIKWPWYVW | 31 | SARS-CoV | Nil | - | Fusion | Plaque assay | |||||||||||||||||
| AVP0551 | AACEVAKNLNESLIDLQELGKYEQYIKW | 28 | SARS-CoV | 42 | % | Fusion | Plaque assay | |||||||||||||||||
| AVP1477 | FKLPLGINITNFRAILTAFS | 20 | SARS-CoV | >500 | IC90 (μg/ml) | S protein | Viral titer | |||||||||||||||||
| AVP1478 | PTTFMLKYDENGTITDAVDC | 20 | SARS-CoV | 112.5±26.3 | IC90 (μg/ml) | S protein | Viral titer | |||||||||||||||||
| AVP1479 | VLYNSTFFSTFKCYGVSATK | 20 | SARS-CoV | >500 | IC90 (μg/ml) | S protein | Viral titer | |||||||||||||||||
| AVP1480 | PALNCYWPLNDYGFYTTSGI | 20 | SARS-CoV | >500 | IC90 (μg/ml) | S protein | Viral titer | |||||||||||||||||
| AVP1481 | RDVSDFTDSVRDPKTSEILD | 20 | SARS-CoV | >500 | IC90 (μg/ml) | S protein | Viral titer | |||||||||||||||||
| AVP1482 | YQDVNCTDVSTAIHADQLTP | 20 | SARS-CoV | 113.0±27.6 | IC90 (μg/ml) | S protein | Viral titer | |||||||||||||||||
| AVP1483 | SNNTIAIPTNFSISITTEVM | 20 | SARS-CoV | >500 | IC90 (μg/ml) | S protein | Viral titer | |||||||||||||||||
| AVP1484 | QYGSFCTQLNRALSGIAAEQ | 20 | SARS-CoV | 24.9±6.2 | IC90 (μg/ml) | S protein | Viral titer | |||||||||||||||||
| AVP1485 | GIGVTQNVLYENQKQIANQF | 20 | SARS-CoV | >500 | IC90 (μg/ml) | S protein | Viral titer | |||||||||||||||||
| AVP1486 | IQKEIDRLNEVAKNLNESLI | 20 | SARS-CoV | 73.5±15.7 | IC90 (μg/ml) | S protein | Viral titer | |||||||||||||||||
| AVP1583 | GINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYE | 37 | SARS-CoV | 0.62 | μM | Virus entry | beta-galactosidase activity | |||||||||||||||||
| AVP1584 | GINASVVNIQKEIDRLNEVAKNLNESLIDL | 30 | SARS-CoV | 0.8 | μM | Virus entry | beta-galactosidase activity | |||||||||||||||||
| AVP1585 | GINASVVNIQKEIDRLNEVAKNL | 23 | SARS-CoV | 1.04 | μM | Virus entry | beta-galactosidase activity | |||||||||||||||||
| AVP1586 | QKQIANQFNKAISQIQESLTTTSTALGKLQDVVNQNAQALNTLVKQ | 46 | SARS-CoV | 3.97 | μM | Virus entry | beta-galactosidase activity | |||||||||||||||||
| AVP1587 | QNQSANQFQKEISQINEVLTTTNTSLGKLQDDVNQNNQSLNTLQKE | 46 | SARS-CoV | 5.07 | μM | Virus entry | beta-galactosidase activity | |||||||||||||||||
| AVP1641 | KKKKYRNIRRPG | 12 | SARS-CoV | 45 | μg/ml | Virus entry | ELISA | |||||||||||||||||
| AVP1705 | ISGINASVVNIQEEIKKLNEEAKKLNESLIDLQEL | 35 | SARS-CoV | 4 | nM | Virus entry | ELISA | |||||||||||||||||
| AVP1706 | ISGINASVVNIQKEIDRLNEVAKNLNESLIDLQEL | 35 | SARS-CoV | 5 | nM | Virus entry | ELISA | |||||||||||||||||
| AVP1707 | IEEINKKVEEIQKKIEELNKKAEELNKKLEELQKK | 35 | SARS-CoV | >100 | μM | Virus entry | ELISA | |||||||||||||||||
| AVP1716 | TLKPIFKLPLGINITNFR | 18 | SARS-CoV | 11 | μM | Virus entry | Luciferase assay | |||||||||||||||||
| AVP1717 | ISGINASVVNIQKEIDRLNEVAKNLNESLIDLQEL | 35 | SARS-CoV | 0.34 | μM(EC50) | Virus entry | Luciferase assay | |||||||||||||||||
| AVP1718 | YENQKQIANQFNKAISQIQESLTTTSTA | 28 | SARS-CoV | 1.16 | μM(EC50) | Virus entry | Luciferase assay | |||||||||||||||||
| AVP1719 | DVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQYI | 48 | SARS-CoV | 2.15 | μM(EC50) | Virus entry | Luciferase assay | |||||||||||||||||
| AVP1720 | IQESLTTTSTALGKLQDVVNQNAQALNTLVKQLSS | 35 | SARS-CoV | ND | μM(EC50) | Virus entry | Luciferase assay | |||||||||||||||||
| AVP1721 | YENQKQIANQFNKAISQIQESLTTTSTALGKLQDVVNQNAQALNTLVKQLSSNFGAISSV | 60 | SARS-CoV | ND | μM(EC50) | Virus entry | Luciferase assay | |||||||||||||||||
| AVP1722 | FGGASCCLYCRCHIDHPNPKGFCDLKGKY | 29 | SARS-CoV | 160 | μM | Replication | MTase Activity Assay | |||||||||||||||||
| AVP1723 | GGASCCLYCRCH | 12 | SARS-CoV | 160 | μM | Replication | MTase Activity Assay | |||||||||||||||||
| AVP1724 | DLKGKYVQIP | 10 | SARS-CoV | Low | μM | Replication | MTase Activity Assay | |||||||||||||||||
| AVP1725 | NCVKMLCTHTGTGQAITVTP | 20 | SARS-CoV | Low | μM | Replication | MTase Activity Assay | |||||||||||||||||
| AVP1726 | PTTCANDP | 8 | SARS-CoV | Low | μM | Replication | MTase Activity Assay | |||||||||||||||||
| AVP1770 | ALNCYWPLNDYGFYTTTGIGYQPYRVVVLSFEL | 33 | SARS-CoV | 41.6 | μM | Virus entry | Plaque assay | |||||||||||||||||
| AVP1822 | YKYRYL | 6 | SARS-CoV | High | - | Virus entry | RT PCR | |||||||||||||||||
| AVP1833 | CANLLLQYGSFCTQLNRALSGIA | 23 | SARS-CoV | 50 | % | Virus entry | Syncitia assay | |||||||||||||||||
| AVP1834 | PSSKRFQPFQQFGRDVSDFT | 20 | SARS-CoV | 50 | % | Virus entry | Syncitia assay | |||||||||||||||||
| AVP1835 | RNTREVFAQVKQMYKTPTLKYFG | 23 | SARS-CoV | Low | - | Virus entry | Syncitia assay | |||||||||||||||||
| AVP1836 | TKFPSVYAWERKKISNCVAD | 20 | SARS-CoV | Low | - | Virus entry | Syncitia assay | |||||||||||||||||
| AVP1837 | KGIYQTSNFRVVPSGDVVRF | 20 | SARS-CoV | Nil | - | Virus entry | Syncitia assay | |||||||||||||||||
| AVP1838 | KSNVVRGWVFGSTMNNKSQS | 20 | SARS-CoV | Nil | - | Virus entry | Syncitia assay | |||||||||||||||||
| AVP1839 | TDAVDCSQNPLAELKCSVKSF | 21 | SARS-CoV | Nil | - | Virus entry | Syncitia assay | |||||||||||||||||
| AVP1840 | TSSMRGVYYPDEIFRSDTLYL | 21 | SARS-CoV | Nil | - | Virus entry | Syncitia assay | |||||||||||||||||
| AVP1841 | YKGYQPIDVVRDLPSGFNTL | 20 | SARS-CoV | Nil | - | Virus entry | Syncitia assay | |||||||||||||||||
| AVP1842 | YNYKYRYLRHGKLRPFERDI | 20 | SARS-CoV | Nil | - | Virus entry | Syncitia assay | |||||||||||||||||
| AVP1857 | NGIGVTQNVLYENQKQIANQFNKAISQIQESLTTTSTA | 38 | SARS-CoV | 0.14 | μM(EC50) | Virus entry | Luciferase assay | |||||||||||||||||
| AVP1858 | IQKEIDRLNEVAKNLNESLIDLQELGK | 27 | SARS-CoV | 1.19 | μM(EC50) | Virus entry | Luciferase assay | |||||||||||||||||
|
||||||||||||||||||||||||
 |
 |